Senestech Inc
NASDAQ:SNES
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (13.5), the stock would be worth $-14.88 (1 048% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.4 | $1.57 |
0%
|
| Industry Average | 13.5 | $-14.88 |
-1 048%
|
| Country Average | 13.3 | $-14.68 |
-1 035%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Senestech Inc
NASDAQ:SNES
|
8.2m USD | -1.4 | -1.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 49.7 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 22.3 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 19.7 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 14.3 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 16.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 13.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.3 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Senestech Inc
Glance View
SenesTech, Inc. engages in the development and commercialization of a proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. The company is headquartered in Flagstaff, Arizona and currently employs 26 full-time employees. The company went IPO on 2016-12-08. The Company’s product ContraPest, is in the pest control industry in attacking the reproductive systems of both male and female rats. ContraPest is a liquid bait containing the active ingredients four vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest has two active ingredients, including 4-VCD and triptolide. Triptolide is derived from the thunder god vine Tripterygium wilfordii, used in traditional Chinese medicines and other over-the-counter supplements. Triptolide affects the reproductive capacity of both male and female rats. VCD is an occupational chemical that selectively destroys ovarian follicles in rats. The firm also continues to research and develop enhancements to ContraPest that align with its target verticals and other potential fertility control options for additional species.
